Tumor lysis syndrome in metastatic breast cancer after a single dose of paclitaxel - 25/02/15
Doi : 10.1016/j.ajem.2014.07.039
Gaurang Nandkishor Vaidya, MBBS ⁎ 
Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY
⁎Corresponding author at: 50 Presidential Plaza, Apt 1504, Syracuse, NY 13202. Tel.: +1 310 923 2034.
Highlights |
• | Paclitaxel is a commonly used cytotoxic agent in metastatic breast cancer and we describe a patient who developed TLS after a single dose of paclitaxel. |
• | Our case is only the second reported case of metastatic breast cancer treated with paclitaxel to develop TLS. |
• | TLS in solid tumors is practically always preventable but has high mortality. |
• | The development of a risk stratification score to assess the need for hospitalization or close observation of these patients and the documentation of appropriate preventive strategies could help prevent such fatal occurrences |
© 2014
Elsevier Inc. Tous droits réservés.
Vol 33 - N° 2
P. 308.e1-308.e2 - février 2015 Retour au numéro
Article précédent
- Seeks, finds, threats: Lyme disease!
- Xavier Muschart, Dominique Blommaert
- Thrombus in acute aortic dissection with atrial fibrillation: a treatment dilemma
- Yasuyuki Shiraishi, Takashi Kohno, Toru Egashira, Yuichiro Maekawa, Yoshitake Yamada, Akihiro Yoshitake, Hideyuki Shimizu, Motoaki Sano, Masahiro Jinzaki, Keiichi Fukuda
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?